MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: New & Novel

Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening

International Journal of Hygiene and Environmental Health 2017 October 7 [Epub ahead of print] [Link] Cherrie JW, McElvenny D, Blyth KG Abstract INTRODUCTION: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a […]

Comments Off on Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Cancers 2017 September [Link] Klampatsa A, Haas AR, Moon EK, Albelda SM Abstract Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs […]

Comments Off on Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Malignant Pleural Mesothelioma: State of the art and advanced cell therapy

European Journal of Medicinal Chemistry 2017 August [Epub ahead of print] [Link] Facchetti G, Petrella F, Spaggiari L, Rimoldi I Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in […]

Comments Off on Malignant Pleural Mesothelioma: State of the art and advanced cell therapy

Intraoperative adjuncts for malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] Chan WH, Sugarbaker DJ, Burt BM Abstract Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic […]

Comments Off on Intraoperative adjuncts for malignant pleural mesothelioma

Novel systemic therapy against malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum […]

Comments Off on Novel systemic therapy against malignant pleural mesothelioma

Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma

Oncotarget 2017 June [Epub ahead of print] [Link] Jacobson BA, Sadiq AA, Tang S, Jay-Dixon J, Patel MR, Drees J, Sorenson BS, Russell SJ, Kratzke RA Abstract Malignant mesothelioma has a poor prognosis for which there remains an urgent need for successful treatment approaches. Infection with the Edmonston vaccine strain (MV-Edm) derivative of measles virus […]

Comments Off on Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

Stem cell research & therapy 2017 May 25 [Link] Pattarozzi A, Carra E, Favoni RE, W├╝rth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A Abstract BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after […]

Comments Off on The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E Abstract INTRODUCTION: BRCA1-associated protein-1, BAP1, is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A and DNA repair. BAP1 mutations are […]

Comments Off on A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells

Molecular Cancer 2017 March [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28288645″>Link] He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y Abstract BACKGROUND: Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding […]

Comments Off on Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells

Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment

Photodiagnosis and photodynamic therapy 2017 February 22 [Epub ahead of print] [Link] Betrouni N, Munck C, Bensoltana W, Baert G, Dewalle-Vignion AS, Scherpereel A, Mordon S Abstract Complete and homogeneous illumination of the target is necessary for the success of a photodynamic therapy (PDT) procedure. In most applications, light dosimetry is done using detectors placed […]

Comments Off on Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment